Follows the recommendation from ISS to vote FOR the transactionBOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek")…
Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the…
Results showed antineoplastic activity in pancreatic tumor cell lines Metabolic and transcriptional findings demonstrate a molecular basis to reduce tumor…
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"…
Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86Updated vaccine to be available in…
Halifax, Nova Scotia--(Newsfile Corp. - September 11, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona")…
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a…
Click here to access webcast replayTop line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer…
PALO ALTO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento…
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as…